Sleep Disturbance and Relapse in Individuals With Alcohol Dependence: An Exploratory Mixed Methods Study
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02181569 |
Recruitment Status :
Completed
First Posted : July 4, 2014
Last Update Posted : July 7, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Alcoholism |
Study Type : | Observational |
Actual Enrollment : | 198 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Sleep Disturbance and Relapse in Individuals With Alcohol Dependence: An Exploratory Mixed Methods Study |
Actual Study Start Date : | July 10, 2014 |
Actual Primary Completion Date : | March 4, 2019 |
Actual Study Completion Date : | March 4, 2019 |

Group/Cohort |
---|
Treatment seeking participants with alcohol dependence
Treatment seeking individuals with alcohol dependence who are admitted into a 28-day inpatient treatment program.
|
- PSQI [ Time Frame: Day 2 of inpatient admission, within 7 days of discharge, and 4-6 weeks after discharge ]The Pittsburgh Sleep Quality Index (PSQI) is a 19-item, self-rated questionnaire used to measure sleep quality and disturbances over a one-month (30 days) time interval. Nineteen individual items generate seven component scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. A global summation score of five or higher is indicative of poor sleep quality (Buysse, Reynolds, Monk, Berman, & Kupfer, 1989). The PSQI has been validated in populations with insomnia and other sleep disorders, with psychiatric patients, and in normal populations (Backhaus, Junghanns, Broocks, Riemann, & Hohagen, 2002; Doi, Minowa, Uchiyama, Okawa, Kim, Shibui, & Kamei, 2000).
- TLFB [ Time Frame: Day 13 and 4-6 weeks after discharge ]The TLFB collects drinking information using personal historical events recounted over a fixed time period (Sobell & Sobell, 1992). It is a standard assessment for measuring alcohol drinking patterns and quantification in treatment programs. The number of items corresponds to the number of days of interest, typically 90, which usually takes about 30 minutes to complete.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
- INCLUSION CRITERIA:
Participants will be eligible for this study if they are:
- 18 years of age or older,
- Enrolled on the screening, assessment and treatment protocol (14-AA-0181)
- Have been an inpatient for 21 days or more preceding discharge,
- Not enrolled onto a pharmacologic intervention study,
- Able to understand the study, and
- Willing to return to the Clinical Center 4-6 weeks after being discharged from inpatient treatment for a follow-up visit.
EXCLUSION CRITERIA:
Participants will be ineligible for this study if they are:
- Less than 18 years of age,
- Unable to understand the purpose of the study,
- Unable to provide informed consent,
- Unable to follow the study design, or
- Unable or unwilling to return to the Clinical Center 4-6 weeks after being discharged from inpatient treatment for a follow-up visit.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02181569
United States, Maryland | |
National Institutes of Health Clinical Center | |
Bethesda, Maryland, United States, 20892 |
Principal Investigator: | Gwenyth R Wallen, Ph.D. | National Institutes of Health Clinical Center (CC) |
Responsible Party: | National Institutes of Health Clinical Center (CC) |
ClinicalTrials.gov Identifier: | NCT02181569 |
Other Study ID Numbers: |
140143 14-CC-0143 |
First Posted: | July 4, 2014 Key Record Dates |
Last Update Posted: | July 7, 2022 |
Last Verified: | April 18, 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Addiction Severity Index Addiction Sleep Measures Sleep Disorders Natural History |
Dyssomnias Parasomnias Alcoholism Alcohol-Related Disorders Substance-Related Disorders |
Chemically-Induced Disorders Mental Disorders Sleep Wake Disorders Nervous System Diseases |